TCA
NBIX icon

Transcend Capital Advisors’s Neurocrine Biosciences NBIX Stock Holding History

Transcend Capital Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$289K Sell
2,194
-325
-13% -$43.1K 0.02% 557
2025
Q4 		$357K Buy
2,519
+299
+13% +$43.3K 0.03% 468
2025
Q3 		$312K Buy
+2,220
New +$301K 0.02% 518

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Transcend Capital Advisors's NBIX Position: Q1 2026 in Review

Transcend Capital Advisors reduced its Neurocrine Biosciences (NBIX) stake by 13% in Q1 2026, selling an estimated $43.1K and leaving 2,194 shares worth $289K. The position accounts for 0.02% of the portfolio, ranked #557.

Transcend Capital Advisors first reported a position in NBIX in Q3 2025 and has held it in 3 quarters since. The position peaked at $357K in Q4 2025. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Transcend Capital Advisors held 2,194 shares of Neurocrine Biosciences worth $289K as of Q1 2026.
  • Transcend Capital Advisors sold 325 Neurocrine Biosciences shares in Q1 2026, an estimated $43.1K.
  • Neurocrine Biosciences made up 0.02% of Transcend Capital Advisors's portfolio in Q1 2026, its #557 holding.
  • Transcend Capital Advisors first reported a position in Neurocrine Biosciences in Q3 2025 and has held it in 3 quarters since.
  • Transcend Capital Advisors's Neurocrine Biosciences position peaked at $357K in Q4 2025.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Transcend Capital Advisors's 13F filing for Q1 2026, filed 13 May 2026.